← brief for 2026-10-22 · Slowing decline

Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy

Key takeaways

A large trial tested a new drug called iptacopan in people with IgA nephropathy. Over 24 months, the drug slowed kidney decline by about 3 points per year compared to a placebo. This is a strong result from a major study, showing the drug can protect kidney function.

Source

Paper · Kidney International · 2026-10-22
https://www.kidney-international.org/article/S0085-2538(26)00826-4/fulltext?rss=yes